Drug
Bgb A333
Bgb A333: highest development phase Phase 1/2, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB-A333 NCT03379259 | Phase 1/2 | Advanced Solid Tumors |
Latest
No recent events.
Follow Bgb A333 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.